China Market Research Company | China Market Entry | China Market Analysis

Life Sciences

Home >> Views >> Life Sciences

Ch Natural Inv (HKG:8250) suspended for transaction, placing

Source：CCMR Data：2012-5-4

Trading in the shares of China Natural Investment Company Limited (HKG:8250) has been suspended at 9:00 a.m. today pending the release of an announcement relating to a notifiable transaction and a placing of shares and convertible bonds.

The share price of the company before suspension was HK$0.124.

Source:chinesestock.org

·Chinese Healthcare Spending

·Monthly Output of Chinese Patent Medicine, Jan.2011-Oct.2012

·Fairwood (HKG:0052) repurchases 41K shares

·Interchina (HKG:0202) places shares for $359M

·Venturepharm (HKG:8225) to halt trading for results release

·Wuyi Pharma (HKG:1889) 2011 net profit RMB57M, down 46%; div HK$0.008

·Lijun (HKG:2005) sinks to red, 2011 NL $41M; div 2 ct

·Healthy Living

·BMS Banks on Innovative Drugs to Double China Sales

·Genetic Technologies executes agreement with Eurofins STA

·Takeda announces establishment of development center in China

·Roche supports animal conservation research

·Fudan-Zhangjiang (HKG:8231) Sees 2011 Net Profit Up Sharply

·IDT acquires 1st BASE oligonucleotide business

·BioDiem licenses LAIV technology to Changchun BCHT

Copyright © 2012-2020 CCMR | China Ceidea Market Research Co., LTD Inc. All rights reserved.
Add：Room 406 Huide Building No 102 Hao Xian Road Yuexiu District Guangzhou Tel：+86-020-28931413 +86 13503051005
BINWEB